Lanreotide Acetate
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
基本情報
- CAS
127984-74-1- 標準SMILES
CC(=O)O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O- InChIKey
DEXPIBGCLCPUHE-UISHROKMSA-N- 分子式
- C56H73N11O12S2
- 平均分子量
- 1,156.4 g/mol
- 単同位体質量
- 1,155.48815915
概要
Lanreotide Acetate is the acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.
名称と識別子
- 優先名称
- Lanreotide Acetate
- IUPAC
- acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
- 英語名
- Lanreotide acetate
- 分子式
- C54H69N11O10S2.C2H4O2
- 分子量
- 1156.38
名称と別名
Lanreotide acetateSomatuline LPSomatuline Depot127984-74-1Somatuline AutogelBIM-23014CIEU56G3J9CRefChem:552347DTXSID201027706L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide, acetateLanreotide (acetate)2378114-72-6
名称をさらに表示
BIM 23014 (acetate)Lanreotide acetate, 10 mM in DMSOLanreotide,Lanreotide acetate,inhibit,hormone,apoptosis,pituitary,BIM23014,Inhibitor,BIM-23014,GH3 cells,tumor,adenoma,GH-secreting,BIM 23014
Somatulineacetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamideL-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2?7)-disulfide, acetate (salt) (9CI); 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane, cyclic peptide deriv.; BIM 23014C; Lanreotide acetate; Somatulina; SomatulineMFCD00873576orb1299003CHEMBL1201184SCHEMBL29405684SCHEMBL29846268
物性
構造計算による物性補完中
- 極性表面積
- 443 Ų
- 水素結合供与体数
- 14
- 水素結合受容体数
- 16
- 回転可能結合数
- 17
- 重原子数
- 81
- 形式電荷
- 0
- 複雑度
- 2,030
実験および物理化学的性質
Human Drugs
Breastfeeding; Lactation; Milk, Human; Hormones; Antineoplastic Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
物理化学的性質
- 外見
- Solid
- 色
- White to off-white
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 42 reports by companies from 3 notifications to the ECHA C&L Inventory.
危険有害性情報
Hazard Classes and CategoriesRepr. 2 (100%)
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Lanreotide acetate
Ambiguous-DILI-concern
2
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
化学と産業
薬理情報
FDA Pharmacological Classification
LANREOTIDE ACETATE
Somatostatin Analog [EPC]; Somatostatin Receptor Agonists [MoA]
MeSH Pharmacological ClassificationSubstances that inhibit or prevent the proliferation of NEOPLASMS.
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…